Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption – an individual-level prescription database study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005, 366: 1267-1278. 10.1016/S0140-6736(05)67394-1.
Walley T, Folino-Gallo P, Stephens P, Van Ganse E: Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol. 2005, 60: 543-551. 10.1111/j.1365-2125.2005.02478.x.
Drug sales statistics in Norway. Norwegian Institute of Public Health, Oslo Norway. [ http://www.legemiddelforbruk.no/english ]
Hartz I, Skurtveit S, Furu K, Njolstad I, Eggen AE: Why do sales of lipid-lowering drugs vary between counties in Norway? Evidence from the OPPHED Health Study 2000–2001. Scand J Prim Health Care. 2006, 24: 115-121. 10.1080/02813430500475365.
The Norwegian Prescription Registry (NorPD). [ http://www.fhi.no/eway/default.aspx?pid=238&trg=MainLeft_5853&MainArea_5811=5853:0:15,3467:1:0:0:::0:0&MainLeft_5853=5825:56740::1:5857:2:::0:0 ]
Furu K, Strøm H, Rønning M, Skurtveit S, Engeland A, Tverdal A: The Norwegian prescription database (NorPD) – a new register for pharmacoepidemiologic research covering a whole nation. 21st ICPE Nashville. Pharmacoepidemiology and Drug Safety. 2005, 14: S49-
Summary of product characteristics (SPC) of drugs licenced for use in Norway 2004. 2004, Norwegian: Felleskatalogen
Kanstrup H, Lassen JF, Heickendorff L, Lauritzen T, Larsen ML: Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients. J Intern Med. 2004, 255 (3): 367-372. 10.1111/j.1365-2796.2003.01299.x.
Norway Statistics. Population by sex and one-year age groups. [ http://statbank.ssb.no//statistikkbanken/default_fr.asp?PLanguage=1 ]
WHO collaborating centre for Drug Statistic and Methodology, ATC classification index with DDDs 2005, Oslo, Norway, 2004.
Hartz I, Eggen AE, Grimsgaard S, Skjold F, Njølstad I: Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study – the Tromsø Study 2001. Eur J Clin Pharmacol. 2004, 60: 643-649. 10.1007/s00228-004-0827-z.
Tonstad S, Rosvold EO, Furu K, Skurtveit S: Undertretament and overtreatment with statins: the Oslo Health Study 2000–2001. J Intern Med. 2004, 255: 494-502. 10.1111/j.1365-2796.2004.01315.x.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002, 360: 7-22. 10.1016/S0140-6736(02)09327-3.
Riahi S, Fonager K, Toft E, Hvilsted-Rasmussen L, Bendsen J, Paaske Johnsen S, Sorensen HT: Use of lipid-lowering drugs during 1991–98 in Northern Jutland, Denmark. Br J Clin Pharmacol. 2001, 52: 307-311. 10.1046/j.0306-5251.2001.01439.x.
Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius AJ, de Boer A: Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?. Br J Clin Pharmacol. 2002, 53: 379-385. 10.1046/j.1365-2125.2002.01562.x.
Larsen J, Andersen M, Kragstrup J, Gram LF: Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993–1998) in a Danish population. Eur J Clin Pharmacol. 2001, 57: 343-348. 10.1007/s002280100307.
Kvan E, Pettersen KI, Landmark K, Reikvam A: Treatment with statins after acute myocardial infarction in patients >/= 80 years: underuse despite general acceptance of drug therapy for secondary prevention. Pharmacoepidemiology and Drug Safety. 2006, 15: 261-267. 10.1002/pds.1172.
Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, Borgstrom F, Jonsson L: Lipid management and cholesterol goal attainment in Norway. American journal of cardiovascular drugs. 2006, 6: 121-128. 10.2165/00129784-200606020-00006.
Larsen J, Andersen M, Kragstrup J, Gram LF: High persistence of statin use in a Danish population: compliance study 1993–1998. Br J Clin Pharmacol. 2002, 53: 375-378. 10.1046/j.1365-2125.2002.01563.x.
Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, Rasmussen S, Kober L, Stender S, Madsen M, Torp-Pedersen C: Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006, 27: 1153-1158. 10.1093/eurheartj/ehi705.
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002, 360: 1623-30. 10.1016/S0140-6736(02)11600-X.
Treatment with lipid-lowering drugs in the prevention of cardiovascular disease [In Norwegian: Behandling med lipidsenkende legemidler for å forebygge hjerte-og karsykdom]. 2003, Norwegian Medicines Agency, Oslo, Norway